Home
Mailbox
Boards
Favorites
Whats Hot!
Login - Join Now!
Search
Search Type
Board
Post
Member
CytoDyn Inc CYDY
Board Mod:
HHIGambler
Asst Mods:
Evil Rabbit
CaptnAmerca
mightycydy
Last Post: 10/30/2025 5:19:16 PM
Board Marks: 394
Posts Today: 0
Board Views Today: 1781
CytoDyn Inc CYDY
CytoDyn Inc. (OTCQB: CYDY)
Company Website:
http://www.cytodyn.com/
CYDY Company Profile
CYDY Time & Sales
CYDY Recent News
CYDY Filings
CYDY Financials
CYDY Buy Rating
My69z
07/02/2025 10:51:49 AM
July 11th is the last IRB meeting
(1)
brentie
07/02/2025 10:50:35 AM
"Third, we have finalized the protocol
(7)
Mr3Putt
07/02/2025 10:38:36 AM
IIRC, It's the Cornell trial, if it
(2)
MJS719
07/02/2025 10:24:14 AM
I noticed on the website that we did or
(1)
dfwl28
07/02/2025 9:51:11 AM
Ohm: "... Bring in a PD-L1 or PD-1
(2)
My69z
07/02/2025 9:43:44 AM
Thx SamaGong!...makes sense when you
(2)
Boatbuilder
07/02/2025 9:02:55 AM
The Morningstar mention is significant.
(2)
SamaGong
07/02/2025 8:37:15 AM
Yeah, adding ICI treatment into the mix
(3)
Plotinus
07/02/2025 8:32:29 AM
A better way of understanding protocol
(16)
Riztheinvestor
07/02/2025 8:11:36 AM
Morally negligent welp theyve
(1)
My69z
07/02/2025 7:18:22 AM
Some studies suggest that modulating
(6)
brentie
07/02/2025 7:14:48 AM
We're getting some coverage...
(24)
My69z
07/02/2025 2:14:40 AM
SK said in the 2022 video we hired a
(18)
HouseofCards
07/02/2025 1:33:23 AM
All this appears to say is that they
(2)
grow
07/02/2025 1:32:16 AM
Thank you for your insights
(1)
chazzledazzle
07/02/2025 1:22:37 AM
PD-L1 is just the perfume needed to get
(1)
chazzledazzle
07/02/2025 1:20:01 AM
This is exactly what I said but in my
(1)
ohm20
07/02/2025 1:12:34 AM
The question I think is what does he
(17)
chazzledazzle
07/02/2025 1:07:49 AM
That is correct. Expect a lag in any
(1)
ohm20
07/02/2025 12:52:05 AM
Heres the study overview. As well as
(8)
ohm20
07/02/2025 12:43:53 AM
OK , in this PR , but do you see
(24)
ohm20
07/02/2025 12:31:46 AM
PD-L1 (programmed death ligand one) is
(18)
grow
07/02/2025 12:14:41 AM
The LinkedIn post from Max carries
(10)
chazzledazzle
07/02/2025 12:14:12 AM
I hope so too. That does make it seem
(3)
Evil Rabbit
07/02/2025 12:11:21 AM
After years of doing this, I feel like
(15)
MJS719
07/01/2025 11:10:22 PM
And then in late May: MONMOUTH
(7)
MJS719
07/01/2025 11:06:31 PM
For the newbies unsure about how we
(8)
Katangolo
07/01/2025 11:02:42 PM
Always awake, always vigilant. Shorts
(1)
Katangolo
07/01/2025 10:37:49 PM
As expected. Bashers always lurking and
(8)
misiu143
07/01/2025 10:06:30 PM
On Linkedin Dr Max L commented to Ken
(11)
chazzledazzle
07/01/2025 9:38:50 PM
Heres some stuff from when we
(1)
chazzledazzle
07/01/2025 9:16:03 PM
Adding checkpoint inhibitors is not a
(2)
chazzledazzle
07/01/2025 8:57:43 PM
OK , in this PR , but do you see
(4)
Plotinus
07/01/2025 8:40:47 PM
Hints on perhaps the next shoe to drop:
(8)
john1234
07/01/2025 8:32:20 PM
I know how it works was a mode on some
Riztheinvestor
07/01/2025 7:54:12 PM
John being a mod is not an easy job
(5)
chazzledazzle
07/01/2025 7:31:49 PM
Id like to extract this statement
(5)
misiu143
07/01/2025 7:29:35 PM
OK , in this PR , but do you see
(1)
misiu143
07/01/2025 7:25:14 PM
If you talking about shareholder letter
john1234
07/01/2025 7:24:54 PM
Just so you know Im not a basher nor
(3)
chazzledazzle
07/01/2025 7:23:40 PM
We have also amended our current
(6)
chazzledazzle
07/01/2025 7:17:40 PM
Investor letter. Website. I can find it
Evil Rabbit
07/01/2025 7:15:25 PM
Plenty of other boards will allow you
(12)
chazzledazzle
07/01/2025 7:15:10 PM
Come on dude, you think we dont know
(2)
misiu143
07/01/2025 7:12:20 PM
Thank you , somehow I miss that . Was
(1)
chazzledazzle
07/01/2025 7:08:18 PM
Check Dr Js comments tgat tve
(1)
chazzledazzle
07/01/2025 7:06:09 PM
Yes
chazzledazzle
07/01/2025 6:59:44 PM
Hi surfrebel, I love your moniker,
(12)
Katangolo
07/01/2025 6:55:47 PM
Not trying to run you off Jon. But
(12)
john1234
07/01/2025 6:46:45 PM
As an investor I dont need this from
(3)
Newer
Older
Recent Articles
Bioretec Ltd Adjusts H1 Report: Financial Highlights and Outlook
Tetragon Financial Group Reveals September 2025 Insights
Bioretec Ltd Updates Financial Report Details for 2025
Loomis Reports Robust Performance in Q3 2025 with Growth
Investments from Optiver and Qube Strengthen McKay Brothers
Strategic Investments by Optiver and QRT Propel McKay Brothers
Mycenax Partners with RIN Institute to Transform ADC Technology
Transforming Enterprises: FastGPT's No-code AI Solutions for 2025
Corbus Pharmaceuticals Moves Forward with Public Offering
S&P 500 Achieves Historic Winning Streak and Market Insights
Key Challenges Highlighted by Michael Saylor for Growth Strategy
Ecer.com Launches Innovative AI Marketplace Strategy for Trade
Bioretec Ltd Revises 2025 Half-Year Report with Key Updates
DigitalXForce Achieves Prestigious Leader Status in IDC Assessment
Danske Bank Sees Positive Trends and Growth for 2025
Sampo plc's Latest Share Buyback Program and Results
Exciting Developments in Kudu Well Appraisal by BW Energy
Aalberts N.V. Strengthens Position with GVT Acquisition
Nxera Pharma's Innovations and Financial Report for 2025
Nxera Pharma Expands Manufacturing to Meet Growing Demand for QUVIVIQ®
Vistin Pharma Reports Strong Q3 Results and Market Growth
Corbus Pharmaceuticals Sets Price for New Stock Offering
Introducing a New Executive Team Member at Realkredit Danmark
Aalberts Enhances Market Position Through Latest Acquisition
Exploring the Future of Green Hydrogen Development
Aker Solutions ASA Sees Revenue Boost in Third Quarter
Aker Solutions Reports Strong Performance in Q3 2025
Aker Solutions’ Record Growth and Promising Future Outlook
Investigation Launched into Conduent's Major Data Breach Event
Vallourec Secures Groundbreaking Contract for Deepwater Project
Essential Patient Inquiries for Portable X-Ray Scheduling
Exploring Affordable Coastal Living Alternatives Near Beaches
Intensity Therapeutics Sees Dip After Surging to New Heights
Marimekko's Strategic Growth and Operations in 2025
SCOR Reports Impressive Q3 2025 Earnings and Growth Metrics
SPIE Reports Robust Growth and Strategic Acquisitions in 2025
Trifork Group Achieves 4.7% Revenue Growth in Q3 Growth Report
Ekspress Grupp’s Revenue Growth and Future Strategies Unveiled
Marimekko Sees Growth in Q3 Revenue and Profits for 2025
Syensqo's Strategic Shift: Selling Oil & Gas Division to SNF
Elis Expands its Reach in Germany with New Acquisition Deal
Biotalys' EVOCA Biofungicide Nears EPA Approval, Changing Crop Protection
Hyundai and NVIDIA Unite for Advanced AI Innovation
Transforming Manufacturing: NVIDIA and SK Group's AI Collaboration
NVIDIA and Samsung Launch Revolutionary AI Manufacturing Factory
NVIDIA and South Korea Join Forces to Revolutionize AI Landscape
Vallourec Secures Major Offshore Contract with TechnipFMC
SCOR Achieves Remarkable Q3 2025 with Strong Net Income
Realsee Partners with Linkhome to Transform Real Estate with AI
Revolutionizing Retirement: How Physicians Are Investing Wisely